help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, M.
Right arrow Articles by Evans, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, M.
Right arrow Articles by Evans, J. L.
The Journal of Clinical Endocrinology & Metabolism Vol. 87, No. 9 4088-4093
Copyright © 2002 by The Endocrine Society


Special Feature

Decreased Insulin Receptor (IR) Autophosphorylation in Fibroblasts from Patients with PCOS: Effects of Serine Kinase Inhibitors and IR Activators

Ming Li, Jack F. Youngren, Andrea Dunaif, Ira D. Goldfine, Betty A. Maddux, Bei B. Zhang and Joseph L. Evans

University of California at San Francisco (M.L., J.F.Y., I.D.G., B.A.M.), Mount Zion Medical Center, San Francisco, California 94143; Northwestern University Medical School (A.D.), Chicago, Illinois 60611; Department of Molecular Endocrinology (B.B.Z.), Merck Research Laboratories, Rahway, New Jersey 07065; and Telik, Inc. (J.L.E.), South San Francisco, California 94080

Address all correspondence and requests for reprints to: Joseph L. Evans, Ph.D., Medical Research Institute, 1001 Bayhill Drive, Suite 208, San Bruno, California 94066. E-mail: . jevansphd{at}earthlink.net

Abstract

Insulin resistance is characteristic of many patients with polycystic ovary syndrome (PCOS). Several studies have suggested that a decrease in insulin receptor (IR) autophosphorylation is a significant component of this resistance. In this study, we have used a highly sensitive ELISA to measure IR tyrosine phosphorylation in fibroblasts from patients with PCOS and healthy control women. After the stimulation of intact fibroblasts with insulin, IR tyrosine phosphorylation in cells from the PCOS patients was decreased by approximately 40% when compared with controls. However, when IR were first immunocaptured from fibroblasts and then stimulated with insulin, neither basal nor insulin-stimulated IR autophosphorylation was different between the two groups, suggesting that a factor independent of the IR was involved. To examine the role of increased serine kinase activity in decreased IR autophosphorylation in PCOS, fibroblasts from PCOS patients were pretreated with inhibitors of serine kinases before insulin stimulation. Pretreatment with H7, a nonspecific protein kinase inhibitor, completely reversed the decrease in insulin-stimulated IR autophosphorylation. Pretreatment with H89, an inhibitor of protein kinase A, partially reversed this function, whereas pretreatment with Gö6983, an inhibitor of protein kinase C, was without effect. We next studied the effects of two small molecule activators of the IR tyrosine kinase: TLK16998 and Merck L7. Both TLK16998 and Merck L7 were able to reverse the impaired insulin-stimulated IR autophosphorylation. In summary, a factor(s) extrinsic to the IR cause impaired IR signaling in fibroblasts from patients with PCOS. Reversal of the impaired IR signaling by inhibitors of serine kinase activity suggests that serine kinase-mediated pathways may be involved in the insulin resistance. Moreover, the observation that TLK16998 and Merck L7 improved IR tyrosine phosphorylation in fibroblasts from patients with PCOS suggests that specific pharmacological therapies might be developed to treat the insulin resistance in PCOS.




This article has been cited by other articles:


Home page
Eur J EndocrinolHome page
M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer
Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.
Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
V. Skov, D. Glintborg, S. Knudsen, T. Jensen, T. A. Kruse, Q. Tan, K. Brusgaard, H. Beck-Nielsen, and K. Hojlund
Reduced Expression of Nuclear-Encoded Genes Involved in Mitochondrial Oxidative Metabolism in Skeletal Muscle of Insulin-Resistant Women With Polycystic Ovary Syndrome
Diabetes, September 1, 2007; 56(9): 2349 - 2355.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
I. Kowalska, M. Straczkowski, A. Nikolajuk, A. Adamska, M. Karczewska-Kupczewska, E. Otziomek, S. Wolczynski, and M. Gorska
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome
Hum. Reprod., July 1, 2007; 22(7): 1824 - 1829.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
K.-M. Seow, C.-C. Juan, Y.-P. Hsu, J.-L. Hwang, L.-W. Huang, and L.-T. Ho
Amelioration of insulin resistance in women with PCOS via reduced insulin receptor substrate-1 Ser312 phosphorylation following laparoscopic ovarian electrocautery
Hum. Reprod., April 1, 2007; 22(4): 1003 - 1010.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Corton, J. I. Botella-Carretero, A. Benguria, G. Villuendas, A. Zaballos, J. L. San Millan, H. F. Escobar-Morreale, and B. Peral
Differential Gene Expression Profile in Omental Adipose Tissue in Women with Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 328 - 337.
[Abstract] [Full Text] [PDF]


Home page
Diabetes CareHome page
Z. T. Bloomgarden
Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions.
Diabetes Care, September 1, 2006; 29(9): 2165 - 2174.
[Full Text] [PDF]


Home page
DiabetesHome page
A. Corbould, H. Zhao, S. Mirzoeva, F. Aird, and A. Dunaif
Enhanced Mitogenic Signaling in Skeletal Muscle of Women With Polycystic Ovary Syndrome
Diabetes, March 1, 2006; 55(3): 751 - 759.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
A. Corbould, Y.-B. Kim, J. F. Youngren, C. Pender, B. B. Kahn, A. Lee, and A. Dunaif
Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired defects in insulin signaling
Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E1047 - E1054.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
V. L. Nelson-Degrave, J. K. Wickenheisser, K. L. Hendricks, T. Asano, M. Fujishiro, R. S. Legro, S. R. Kimball, J. F. Strauss III, and J. M. McAllister
Alterations in Mitogen-Activated Protein Kinase Kinase and Extracellular Regulated Kinase Signaling in Theca Cells Contribute to Excessive Androgen Production in Polycystic Ovary Syndrome
Mol. Endocrinol., February 1, 2005; 19(2): 379 - 390.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
R. Azziz
Polycystic Ovary Syndrome, Insulin Resistance, and Molecular Defects of Insulin Signaling
J. Clin. Endocrinol. Metab., September 1, 2002; 87(9): 4085 - 4087.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2002 by The Endocrine Society